Eton Pharmaceuticals, Inc. (ETON)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Eton Pharmaceuticals, Inc. reported revenue of $79.95M, up 104.9% from the prior year. The company ran a net loss, with a net margin of -5.8% and a gross margin of 53.5%. It held $92.11M in total assets against $65.96M in total liabilities.
Key ratios (FY2025)
53.5%
Gross margin
-1.1%
Operating margin
-5.8%
Net margin
-17.6%
Return on equity
+104.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.95M | $39.01M | $31.64M | $21.25M | $21.83M | $39.0K | $959.0K | — | — |
| Cost of Revenue | $37.21M | $15.60M | $10.58M | $6.93M | $2.83M | $436.0K | $453.0K | — | — |
| Gross Profit | $42.74M | $23.41M | $21.06M | $14.32M | $19.00M | -$397.0K | $506.0K | — | — |
| Operating Income | -$844.0K | -$2.60M | -$1.19M | -$8.26M | -$1.50M | -$27.11M | -$18.60M | -$10.32M | — |
| Net Income | -$4.60M | -$3.82M | -$936.0K | -$9.02M | -$1.96M | -$27.97M | -$18.32M | -$12.74M | — |
| EPS (Diluted) | $-0.17 | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | — | — | — |
| Total Assets | $92.11M | $76.12M | $31.74M | $25.03M | $27.46M | $26.32M | $17.07M | $28.33M | $13.44M |
| Total Liabilities | $65.96M | $51.70M | $16.26M | $11.95M | $9.84M | $10.66M | $6.52M | $2.02M | $1.31M |
| Shareholders' Equity | $26.15M | $24.43M | $15.48M | $13.08M | $17.63M | $17.63M | $10.55M | $26.30M | -$6.87M |
| Cash & Equivalents | $25.94M | $14.94M | $21.39M | $16.30M | $14.41M | $21.30M | $12.07M | $26.73M | $13.16M |
| Operating Cash Flow | $10.52M | $969.0K | $6.82M | $4.82M | -$4.72M | -$22.35M | -$18.03M | -$8.14M | — |
| Capital Expenditures | $333.0K | $26.0K | $0 | $38.0K | $9.0K | $50.0K | $1.10M | $236.0K | — |
| Shares Outstanding | 27.05M | 26.71M | 25.69M | 25.35M | 24.63M | 24.31M | 17.88M | 17.61M | 6.00M |